Capricor Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CAPR research report →
Range $3.5 – $25
Price Chart
About the company
Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine.
- CEO
- Linda Marbán
- IPO
- 2007
- Employees
- 231
- HQ
- San Diego, CA, US
Get TickerSpark's AI analysis on CAPR
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $439.55M
- P/E
- -2.85
- Fwd P/E
- 22.32
- PEG
- 0.08
- P/S
- 0.00
- P/B
- 2.09
- EV/EBITDA
- 0.42
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -56.71%
- ROIC
- -50.85%
Latest fiscal year · YoY change
- Revenue
- $0-100.0%
- Gross Profit
- $0+100.0%
- Op Income
- $-108,142,130
- Net Income
- $-105,043,946-159.6%
- EPS
- $-2.26-96.5%
- OCF Growth
- -74.5%
- FCF Growth
- -75.1%
- 52W High
- $40.37
- 52W Low
- $2.96
- 50D MA
- $8.04
- 200D MA
- $19.64
- Beta
- 0.53
- RSI (14)
- 46
- Avg Volume
- 4.70M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Capricor said its deramiocel BLA is in final FDA review ahead of the November 22 PDUFA date, with management leaning on HOPE-3 efficacy, longer-term data, and manufacturing readiness as it awaits a decision.· November 10, 2026
- FDA extended the PDUFA target action date to November 22, 2026 after agreeing to review a major BLA amendment with additional HOPE-3 data and analyses.
- Management emphasized HOPE-3 met its primary endpoint: upper-limb function slowed versus placebo with a p-value of 0.029 and an absolute difference of 1.1 points on PUL 2.0.
- The company highlighted 24-month open-label data, saying placebo patients slowed to about 0.5 points of decline after switching to deramiocel, a 76% slowing versus their first year on placebo.
- Cardiac data remained a key theme: in patients with existing cardiomyopathy, ejection fraction improved by about 2.8 percentage points relative to placebo, though the overall population did not reach statistical significance.
- Capricor said its San Diego GMP facility is ready for an initial launch, cash was $198.5 million at September 30, 2026, and it cut workforce by about 10% to pace spending.
Capricor reported no revenue for the third quarter of 2026 or 2025. Operating expenses were approximately $44.7 million in Q3 2026 versus approximately $20.3 million in Q3 2025, driven mainly by pre-commercial activities and manufacturing scale. Net loss was approximately $42.7 million, or $0.73 per share, versus a net loss of approximately $24.6 million, or $0.54 per share, a year ago. For the nine months ended September 30, 2026, net loss was approximately $117.3 million versus approximately $74.9 million in the prior-year period. Cash, cash equivalents, restricted cash and marketable securities totaled approximately $198.5 million at September 30, 2026, and management said that is sufficient to fund operations for at least the next 12 months. For forward guidance, the company said FDA review remains ongoing, the PDUFA date is November 22, 2026, arbitration with NS Pharma is expected to commence in mid-2027, and the second-floor facility validation is targeted for the first half of 2020 as stated on the call.
Linda Marbán framed the quarter around regulatory execution and a stronger evidence package for deramiocel. She said the company submitted a major amendment with about 30,000 pages of materials, including 24-month HOPE-3 open-label data, an integrated efficacy summary, and more than 900 robustness reanalyses, and argued the totality of evidence supports the refined upper-limb indication. Her tone was confident and resolute, repeatedly stressing that the company believes the data stand on their own and that it is prepared for approval, launch, or even a CRL scenario.
Anthony J. Bergmann focused on the balance sheet, spending, and runway. He said Capricor ended Q3 with approximately $198.5 million in cash, cash equivalents, restricted cash and marketable securities, had no ATM sales this year, and expects existing resources to fund operations for at least the next 12 months. He also quantified the cost base: Q3 operating expenses were approximately $44.7 million, up from approximately $20.3 million, and net loss widened to approximately $42.7 million, or $0.73 per share, from approximately $24.6 million, or $0.54 per share, reflecting pre-commercial work and manufacturing scale.
Analysts pressed on whether the cardiac data could support a broader label or future expansion, and management said the cardiomyopathy findings are compelling but that any label details are not being disclosed yet. Questions also focused on manufacturing, where Linda said the first-floor clean room can support about 250 patients per year, the second-floor buildout could support about 2,500 patients annually and up to 10,000 doses per year, and she does not expect supply to be a launch constraint. On NS Pharma, she said Capricor is preparing for an independent launch and does not expect the arbitration to block patient access, while on a possible CRL she said the company would assess FDA feedback before deciding whether any additional trial would be justified.
The bull case on this call is that Capricor says it now has a more complete and more durable dataset supporting deramiocel, including a positive randomized HOPE-3 primary endpoint, supportive open-label follow-up, and integrated analyses across two placebo-controlled studies. Management also pointed to manufacturing readiness, a strong cash position, and a launch plan already underway, which reduces execution uncertainty if approval comes through. The company’s confidence was reinforced by external recognition, including the Lancet publication and an AHA award for the cardiac data.
The main risks are that FDA could still issue a CRL or require additional clinical work, and management acknowledged that outcome remains possible even though they believe the agency has enough data. The company also faces ongoing uncertainty around the NS Pharma arbitration and has already reduced its workforce by about 10% while moderating pipeline work, which signals the need to conserve cash. Finally, the cardiac benefit was not significant across the full population, leaving some uncertainty around how much of that data will matter in the final label or in future expansion.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 90.9%
- Shares Outstanding
- 57.91M
- Float Shares
- 52.66M
of shares held by institutions
196 13F filers
Buy/sell ratio 0.65. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for CAPR, newest first.
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock, Inc. | 4.18M | ▲ 33.14K |
| Tang Capital Management LLC | 4.10M | ▲ 700.00K |
| Montanova Capital, LLC | 4.09M | ▲ 274.18K |
| State Street Corp | 3.02M | ▼ 378.13K |
| Vanguard Group Inc | 2.56M | ▲ 355.16K |
| Vanguard Capital Management LLC | 2.30M | ▲ 5.71K |
| Goldman Sachs Group Inc | 1.58M | ▲ 666.15K |
| Ra Capital Management, L.P. | 1.51M | 0 |
| Ubs Group AG | 1.40M | ▲ 783.70K |
| Boxer Capital Management, LLC | 1.40M | ▲ 805.16K |
| Geode Capital Management, LLC | 1.14M | ▼ 234.60K |
| Jones Hill Capital LP | 892.53K | ▲ 471.78K |
Held by 190 ETFs
Biggest fund positions in CAPR by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 25, 26 | Krasney Karen | other | 24,100 |
| Jun 25, 26 | Krasney Karen | other | 24,100 |
| Jun 25, 26 | Krasney Karen | sell | 24,100 |
| Jun 25, 26 | Bergmann Anthony | other | 24,100 |
| Jun 25, 26 | Bergmann Anthony | other | 24,100 |
| Jun 25, 26 | Bergmann Anthony | sell | 24,100 |
| Jun 22, 26 | Krasney Karen | other | 500 |
| Jun 24, 26 | Krasney Karen | other | 400 |
| Jun 22, 26 | Krasney Karen | other | 500 |
| Jun 24, 26 | Krasney Karen | other | 400 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our CAPR coverage
Recent articles, reports, and earnings notes.

Vesicor Therapeutics Is Going Public via SPAC — Here's the Setup
Vesicor Therapeutics is a development-stage microvesicle-based biotech going public through a merger with Black Hawk Acquisition Corp (NASDAQ: BKHA). The setup offers a small, pre-commercial oncology platform with a $70 million headline valuation, but shareholders should watch redemption risk, dilution, and whether the deal can actually deliver enough cash to fund development.

Should You Buy the Parabilis Medicines IPO? Here's the Setup
Parabilis Medicines (NASDAQ: PBLS) is expected to list on 2026-06-10, with shares priced at $17.00 to $19.00. The company is offering 25,000,000 shares and is targeting a $546,250,000 market cap. The bull case is a differentiated oncology platform; the bear case is a clinical-stage biotech with no disclosed commercial revenue.
Want a deeper read on CAPR?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Capricor Therapeutics Provides Regulatory Update on Deramiocel BLA for Duchenne Muscular Dystrophy
globenewswire.com · Nov 20
Capricor Stock in Focus Ahead of FDA Decision on Duchenne Therapy Deramiocel
benzinga.com · Nov 18
Capricor Stock Rises: What's Going On?
benzinga.com · Nov 17
Capricor Stock Rises Despite Wider-Than-Expected Q3 Loss
benzinga.com · Nov 11
Capricor Therapeutics, Inc. (CAPR) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 10
Capricor Therapeutics Q3 Earnings Call Highlights
marketbeat.com · Nov 10
Capricor Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
globenewswire.com · Nov 10
Capricor's HOPE-3 Phase 3 Cardiac Results for Deramiocel Win American Heart Association Outstanding Research Award in Pediatric Cardiology
globenewswire.com · Nov 9
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.